Avrio MedTech

Avrio MedTech operates at the intersection of clinical neurotechnology, epilepsy diagnostics, research software and AI-enabled biomedical analytics. Its target users include epilepsy clinicians, neuroscience researchers, neuromodulation teams, therapeutic developers and EEG-equipment providers. Halyzia is differentiated from general-purpose EEG viewers by concentrating on quantitative intracranial recordings, including synchronized micro- and macro-electrode data and high-frequency signals reported at up to 32 kHz. The platform combines automated detection with clinician-oriented visualization, biomarker quantification and interactive brain mapping, while custom pipelines and integration services extend its relevance to research collaborations and study programs. The competitive set includes established EEG-analysis vendors, hospital-developed research platforms and specialist neurotechnology software teams, but no specific named competitor is identified in the available company information, so a direct feature-by-feature comparison is not possible. Avrio's strongest apparent advantage is the combination of domain-specific epilepsy analytics, the WALFRID patented detector and a no-code workflow that can be deployed standalone or integrated with existing systems. Its main market-position limitation is the lack of publicly documented scale, regulatory milestones, customer adoption metrics or large commercial partnerships.

Avrio MedTech's trajectory is consistent with an early-stage specialist software company moving from academic and clinical research into deployable epilepsy-analysis products. The company was founded in 2023 and has reported one grant round of approximately €75,000, equivalent to about $81,000 for this profile. Its technology base draws on more than a decade of work associated with CerCo/CNRS, Toulouse University Hospital and ENAC, giving the business a research-heavy foundation while its product portfolio indicates increasing service and commercialization breadth. Halyzia provides a platform product, while advanced iEEG analytics and Halyzia analysis-as-a-service create additional routes to revenue through custom processing, biomarker extraction, study support and client-data analysis. The stated ability to run Halyzia standalone, on a server or integrated with existing EEG-review systems could reduce adoption friction for research and clinical teams. WALFRID's patented wavelet-based fast-ripple detection is another identifiable intellectual-property milestone. Growth should therefore be viewed as technically promising but commercially unquantified.